Clinical trial · no report yet · Phase 3
HARMONi-GI3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- NCT07228832 ↗
- Recruiting
- Summit Therapeutics
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Drug: Ivonescimab Injection; Drug: Bevacizumab Injection
- Arms
- Arm A: Ivonescimab in combination with mFOLFOX6 · Experimental
- Arm B: Bevacizumab in combination with mFOLFOX6 · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- PFS by IRRC based on RECIST v1.1
- Sponsor
- Summit Therapeutics
- Start
- Nov 18, 2025
- Primary completion
- May 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07228832 · updated Oct 6, 2026